Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled. The post Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test appeared first on Investor's Business Daily.#gilead #trodelvy #gild #gileadsciencesstock
Source: Reuters: Health - Category: Consumer Health News Source Type: news